MGC Pharmaceuticals has welcomed Evan Hayes, Sabina Suljaković and Amir Polak to the team, who each bring extensive experience in the biopharma space to MGC Pharma.
MGC Pharmaceuticals Ltd (ASX: MXC), a European based biopharma company specializing in the production and development of phytocannabinoid-derived medicines, is pleased to announce it has strengthened its Board and leadership team with biopharma industry expertise following the appointment of Evan Hayes as an Independent NonExecutive Director and Strategic Advisor, Sabina Suljaković as Qualified Person and Head of the Quality Assurance in Slovenia and Amir Polak as Chief Technology Officer and Head of Pharmaceutical Production.
These appointments are strategically important for MXC as the Company continues to build a high-quality biopharma team. All three members bring extensive knowledge of the biopharma industry and accelerate the delivery of MXC's growth strategy to become a leading biopharma company that produces and manufactures high-quality medicinal cannabis products that are available globally.
Evan Hayes appointed as Independent Non-Executive Director and Strategic Advisor
Evan Hayes is a highly experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes graduated with a Master of Science 1st Class Honours (Biotechnology) from the National University of Ireland, Galway and prior to this, he finished first in his class from the National University of Ireland, Cork with a Bachelor of Science degree (Honours).
Mr Hayes' has also won the Daniel O'Carroll Award for Scientific Research. Mr Hayes is currently the Asia Pacific Managing Director of Factors Group, Canada's largest natural health company. Prior to this Mr Hayes was the Director of Sourcing and Product Development at Australia's largest natural health company, Blackmores, leading the Procurement, Technical, New product development, and Strategic sourcing divisions and managed a budget of $250m.
Mr Hayes was also Executive Director, Chairman of the Scientific Advisory Board and Chief Scientific Officer of BioCeuticals, part of the Blackmores group, where he led the product development team which delivered sales from new product development of over $120m in 5 years. During his career, Mr Hayes has worked across Europe, the USA and in Australia and has exceptionally strong knowledge of both the FDA and the TGA regulation.
Mr Hayes will receive the standard Non-Executive Director fee of $48k per annum and the Board will be finalising terms of the engagement as Strategic Advisor to include an incentive equity package, the Company will update the market on these details once agreed.
Key Pharma industry appointments to the senior management and production team
Additionally, Sabina Suljaković joins MXC as a Qualified Person and Head of the Quality Assurance Department at the Company's EU GMP facility in Slovenia and Amir Polak has joined as Chief Technology Officer and Head of Pharmaceutical Production. Sabina brings vast experience in the quality leadership from her previous managerial roles at leading pharmaceutical companies which includes PharmaSwiss (a Bausch Health company). Sabina's experience will be vital in taking the Company to its next phase of growth by ensuring the highest quality standards are achieved.
This is aligned with the Company's ambition of producing high-quality phytocannabinoid medicine to meet all strict EU regulatory requirements. Sabina holds MSc in Pharmacy from the University of Ljubljana, is a registered Pharmacist at the Ministry of Health and registered Qualified Person and Responsible Person at the Slovenian Agency for medicines and medical devices. Amir was previously part of the senior leadership team and co-founder at Green City Ltd, head of chemical production at Nano-Dimension, project co-ordinator for Teva Pharmaceuticals and has been a consultant in the industry for over 10 years.
Amir brings extensive production experience to the Company and is specialised in "Lab to Plant" development of complex projects. Amir holds MSc in Chemistry from the Hebrew University-Jerusalem. Amir has been consulting with MGC Pharma and is now full time.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "We are delighted to welcome Evan, Sabina and Amir to MGC Pharmaceuticals and have no doubt their respective experience and expertise will be highly valuable.
2020 has been a strategically important year for the Company and strengthening our leadership team with Evan, Sabina and Amir is a testament to how far the Company has come. Roby Zomer, Co-founder and Managing Director of MGC Pharma
Mr. Zomer went on to say that "[MGC] are focused on building and strengthening our biopharma specific expertise with high quality people in order to achieve our goals."
To learn more about MGC Pharma, visit the company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors